GSK confident it can prevail in vaccine battle

GSK's battle to win over the $2 billion market for cervical cancer vaccines has experienced a few big setbacks. French health officials are now recommending against paying for Cervarix and the FDA has lingered long over GSK's application for approval. But Glaxo U.S. pharma chief Chris Viehbacher (photo) insists in a talk with the Wall Street Journal that all is well. Viehbacher says that at the end of the day, head-to-head study data will prove too compelling for the regulators on both sides of the Atlantic to ignore. Meanwhile, though, Merck's Gardasil continues to solidify its position in the market.

- read the report in the Wall Street Journal

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.